Hydrochloric Acid

Hydrochloric Acid

SCHEMBL2266110

Cc1cccc(C)c1-[n+]1ccc(-c2cc[n+](C(C)P(=O)(O)O)cc2)cc1.[Cl-].[Cl-]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ ACP3 P15309 1/20 0.35
▸ FDPS P14324 3/20 0.33
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2258996 0.87 FDPS (0.32) FDPSKDM4EALDH1A1LMNAHTT
SCHEMBL5565745 0.86 KDM4E (0.31) KDM4EALDH1A1LMNAHTTSMN1; SMN2
Hydrochloric Acid SCHEMBL1227055 0.83 ACP3 (0.34) ACP3FDPSKDM4EALDH1A1LMNA
Hydrochloric Acid SCHEMBL2899630 0.81 ACP3 (0.43) ACP3FDPSKDM4EALDH1A1LMNA
SCHEMBL1226946 0.81 ACP3 (0.35) ACP3KDM4EALDH1A1LMNAHTT
Bromide SCHEMBL1227449 0.79 LMNA (0.36) ACP3KDM4EALDH1A1LMNAHTT
Hydrochloric Acid SCHEMBL2263262 0.78 MMP8 (0.36) FDPSKDM4EALDH1A1LMNAHTT
Hydrochloric Acid SCHEMBL3143919 0.78 CYP2A6 (0.36) KDM4EALDH1A1
Hydrochloric Acid SCHEMBL604178 0.77 FDPS (0.33) FDPSKDM4EALDH1A1
Hydrochloric Acid SCHEMBL3930213 0.77 FDPS (0.32) FDPSKDM4EALDH1A1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS NTERA LIMITED (IE) 2009-10-15 — — US claimed
US-20060110638-A1 Electrochromic compounds NTERA LIMITED (IE) 2006-05-25 — — US claimed
EP-1443091-A1 Electrochromic compounds Ntera Limited (IE) 2004-08-04 — — EP claimed
US-8999430-B2 Method of manufacturing display element KONICA MINOLTA HOLDINGS, INC. (JP) 2015-04-07 — — US disclosed
EP-2149816-B1 METHOD OF MANUFACTURING AN ELECTROCHROMIC DISPLAY ELEMENT KONICA MINOLTA HOLDINGS INC (JP) 2014-05-07 — — EP disclosed
US-8014056-B2 Display element and method of driving the same KONICA MINOLTA HOLDINGS, INC. (JP) 2011-09-06 — — US disclosed
US-8004742-B2 Electrochromic display device KONICA MINOLTA HOLDINGS, INC. (JP) 2011-08-23 — — US disclosed
US-20100166946-A1 METHOD OF MANUFACTURING DISPLAY ELEMENT KONICA MINOLTA HOLDINGS, INC. (JP) 2010-07-01 — — US disclosed
US-20100091353-A1 DISPLAY ELEMENT AND METHOD OF DRIVING THE SAME KONICA MINOLTA HOLDINGS, INC. (JP) 2010-04-15 — — US disclosed
EP-2149816-A1 METHOD FOR PRODUCTION OF DISPLAY ELEMENT Konica Minolta Holdings, Inc. (JP) 2010-02-03 — — EP disclosed
US-20090316249-A1 ELECTROCHROMIC DISPLAY DEVICE KONICA MINOLTA HOLDINGS, INC. (JP) 2009-12-24 — — US disclosed
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS NTERA LIMITED (IE) 2009-10-15 — — US disclosed
US-7567371-B2 Electrochromic compounds NTERA LIMITED (IE) 2009-07-28 — — US disclosed
EP-2040115-A1 ELECTROCHROMIC DISPLAY DEVICE Konica Minolta Holdings, Inc. (JP) 2009-03-25 — — EP disclosed
US-20060110638-A1 Electrochromic compounds NTERA LIMITED (IE) 2006-05-25 — — US disclosed
EP-1443091-A1 Electrochromic compounds Ntera Limited (IE) 2004-08-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090259042-A1 ELECTROCHROMIC COMPOUNDS ETV6, HCN2, EED ACP3 2868/4885FDPS 3265/4885KDM4E 1692/4885
US-20060110638-A1 Electrochromic compounds ETV6, HCN2, EED ACP3 2868/4885FDPS 3265/4885KDM4E 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback